StockMarketWire.com - Shield Therapeutics said that European distribution partner Norgine had launched its iron deficiency treatment in the UK.
Sheild in September licensed the so-called Feraccru treatment to Norgine in most European territories.
'Since announcing the licence agreement in September 2018, we have been working closely with Norgine to transfer knowledge and responsibilities from Shield to them and the UK launch demonstrates that this transition period is progressing well,' chief executive Carl Sterritt said.
At 1:10pm: [LON:STX] Shield Therapeutics Plc share price was 0p at 34p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.